Aug 29, 2023
CEO, Dr. George Frodsham, Featured at the Science Museum
At the heart of the gallery are stories from more than 60 engineers, working in a broad range of industries, such as biotech, farming, fashion, and robotics.
LONDON, August 30, 2023 – MediSieve announced the participation of its CEO, Dr. George Frodsham, in the Science Museum's latest exhibition. This summer, the prestigious Science Museum unveiled a new, free gallery dedicated to showcasing engineering innovations that have significantly transformed the world.
This gallery celebrates the diversity and creativity of the engineering field, featuring the inspiring stories of over 60 engineers. Dr. Frodsham is honored to be part of this exhibition. He shared his excitement: "It's incredibly exhilarating to be featured among such esteemed innovators in the Science Museum. This gallery not only highlights our individual contributions but also sheds light on the collaborative spirit that drives innovation. Our team at MediSieve is deeply inspired by this recognition and remains committed to advancing healthcare."
The gallery at the Science Museum offers an interactive space where visitors can learn about the transformative power of engineering. It serves as a platform to demonstrate the far-reaching impacts of engineers in varied industries, including biotech, farming, fashion, and robotics.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: